Safety and Intraocular Pressure (IOP)-Lowering Efficacy of AL-39256 in Patients With Open-Angle Glaucoma or Ocular Hypertension

Alcon Research104 enrolled

Overview

The purpose of this study is to evaluate the safety and intraocular pressure (IOP)-lowering efficacy of AL-39256 in patients with open-angle glaucoma or ocular hypertension.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

DOUBLE

Enrollment

104

Conditions

Open-Angle Glaucoma Ocular Hypertension

Interventions

AL-39256 Ophthalmic Suspension, 1%DRUG

Latanoprost Ophthalmic Solution, 0.005%DRUG

VehicleDRUG

Inactive ingredients used as a placebo comparator

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Diagnosed with open-angle glaucoma or ocular hypertension. * Other protocol-defined inclusion criteria may apply. Exclusion Criteria: * Females of childbearing potential. * Other protocol-defined exclusion criteria may apply.

Outcomes

Primary Outcomes

Mean change from baseline in IOP

Time frame: Week 4

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.